NOTICE: Labnodes will be unavailable on Sunday March 4th for scheduled maintenance from 6-11AM central time.
  1. Micropapillary colorectal carcinoma: clinical, pathological and molecular properties, including evidence of epithelial-mesenchymal transition. Gonzalez RS, Huh WJ, Cates JM, Washington K, Beauchamp RD, Coffey RJ, Shi C (2017) Histopathology 70(2): 223-231
    › Primary publication · 27560620 (PubMed)
  2. The MAPK pathway regulates intrinsic resistance to BET inhibitors in colorectal cancer. Ma Y, Wang L, Neitzel LR, Loganathan S, Tang N, Qin L, Emily CE, Guo Y, Knapp S, Beauchamp RD, Lee E, Wang J (2016) Clin Cancer Res
    › Primary publication · 27678457 (PubMed)
  3. Evaluation of frozen tissue-derived prognostic gene expression signatures in FFPE colorectal cancer samples. Zhu J, Deane NG, Lewis KB, Padmanabhan C, Washington MK, Ciombor KK, Timmers C, Goldberg RM, Beauchamp RD, Chen X (2016) Sci Rep : 33273
    › Primary publication · 27623752 (PubMed) · PMC5021945 (PubMed Central)
  4. Comparison of Nanostring nCounter® Data on FFPE Colon Cancer Samples and Affymetrix Microarray Data on Matched Frozen Tissues. Chen X, Deane NG, Lewis KB, Li J, Zhu J, Washington MK, Beauchamp RD (2016) PLoS One 11(5): e0153784
    › Primary publication · 27176004 (PubMed) · PMC4866771 (PubMed Central)
  5. Adenoma-like adenocarcinoma: a subtype of colorectal carcinoma with good prognosis, deceptive appearance on biopsy and frequent KRAS mutation. Gonzalez RS, Cates JM, Washington MK, Beauchamp RD, Coffey RJ, Shi C (2016) Histopathology 68(2): 183-90
    › Primary publication · 25913616 (PubMed) · PMC4619179 (PubMed Central)
  6. Small molecule/ML327 mediated transcriptional de-repression of E-cadherin and inhibition of epithelial-to-mesenchymal transition. An H, Stoops SL, Deane NG, Zhu J, Zi J, Weaver C, Waterson AG, Zijlstra A, Lindsley CW, Beauchamp RD (2015) Oncotarget 6(26): 22934-48
    › Primary publication · 26082441 (PubMed) · PMC4673210 (PubMed Central)
  7. Optimization of a small molecule probe that restores e-cadherin expression. Brogan JT, Stoops SL, Brady S, An H, Weaver C, Daniels JS, Beauchamp RD, Lindsley CW, Waterson AG (2015) Bioorg Med Chem Lett 25(19): 4260-4
    › Primary publication · 26299347 (PubMed) · PMC4567403 (PubMed Central)
  8. Linking patient outcome to high throughput protein expression data identifies novel regulators of colorectal adenocarcinoma aggressiveness. French CL, Ye F, Revetta F, Zhang B, Coffey RJ, Washington MK, Deane NG, Beauchamp RD, Weaver AM (2015) F1000Res : 99
    › Primary publication · 26097693 (PubMed) · PMC4457132 (PubMed Central)
  9. Claudin-7 expression induces mesenchymal to epithelial transformation (MET) to inhibit colon tumorigenesis. Bhat AA, Pope JL, Smith JJ, Ahmad R, Chen X, Washington MK, Beauchamp RD, Singh AB, Dhawan P (2015) Oncogene 34(35): 4570-80
    › Primary publication · 25500541 (PubMed) · PMC4804637 (PubMed Central)
  10. Nuclear factor of activated T-cell activity is associated with metastatic capacity in colon cancer. Tripathi MK, Deane NG, Zhu J, An H, Mima S, Wang X, Padmanabhan S, Shi Z, Prodduturi N, Ciombor KK, Chen X, Washington MK, Zhang B, Beauchamp RD (2014) Cancer Res 74(23): 6947-57
    › Primary publication · 25320007 (PubMed) · PMC4252979 (PubMed Central)